BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15967876)

  • 1. Intracellular K+ is required for the inactivation-induced high-affinity binding of cisapride to HERG channels.
    Lin J; Guo J; Gang H; Wojciechowski P; Wigle JT; Zhang S
    Mol Pharmacol; 2005 Sep; 68(3):855-65. PubMed ID: 15967876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.
    Chen J; Seebohm G; Sanguinetti MC
    Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12461-6. PubMed ID: 12209010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
    Guo J; Gang H; Zhang S
    J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular potassium dependency of block of HERG by quinidine and cisapride is primarily determined by the permeant ion and not by inactivation.
    Barrows B; Cheung K; Bialobrzeski T; Foster J; Schulze J; Miller A
    Channels (Austin); 2009; 3(4):239-48. PubMed ID: 19617705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
    Sánchez-Chapula JA; Navarro-Polanco RA; Sanguinetti MC
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec; 370(6):484-91. PubMed ID: 15558243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states.
    Walker BD; Singleton CB; Bursill JA; Wyse KR; Valenzuela SM; Qiu MR; Breit SN; Campbell TJ
    Br J Pharmacol; 1999 Sep; 128(2):444-50. PubMed ID: 10510456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
    Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
    J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes.
    Suessbrich H; Schönherr R; Heinemann SH; Attali B; Lang F; Busch AE
    Br J Pharmacol; 1997 Mar; 120(5):968-74. PubMed ID: 9138706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel.
    Potet F; Bouyssou T; Escande D; Baró I
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1007-12. PubMed ID: 11714889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional interaction between extracellular sodium, potassium and inactivation gating in HERG channels.
    Mullins FM; Stepanovic SZ; Gillani NB; George AL; Balser JR
    J Physiol; 2004 Aug; 558(Pt 3):729-44. PubMed ID: 15169846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
    Luo T; Luo A; Liu M; Liu X
    Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
    Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
    J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing the interaction between inactivation gating and Dd-sotalol block of HERG.
    Numaguchi H; Mullins FM; Johnson JP; Johns DC; Po SS; Yang IC; Tomaselli GF; Balser JR
    Circ Res; 2000 Nov; 87(11):1012-8. PubMed ID: 11090546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural determinants for high-affinity block of hERG potassium channels.
    Mitcheson J; Perry M; Stansfeld P; Sanguinetti MC; Witchel H; Hancox J
    Novartis Found Symp; 2005; 266():136-50; discussion 150-8. PubMed ID: 16050266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical basis for binding and voltage-dependent block of hERG channels by structurally diverse drugs.
    Sanguinetti MC; Chen J; Fernandez D; Kamiya K; Mitcheson J; Sanchez-Chapula JA
    Novartis Found Symp; 2005; 266():159-66; discussion 166-70. PubMed ID: 16050267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
    Kikuchi K; Nagatomo T; Abe H; Kawakami K; Duff HJ; Makielski JC; January CT; Nakashima Y
    Br J Pharmacol; 2005 Mar; 144(6):840-8. PubMed ID: 15778703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
    Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
    Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.
    Thomas D; Wendt-Nordahl G; Röckl K; Ficker E; Brown AM; Kiehn J
    J Pharmacol Exp Ther; 2001 May; 297(2):753-61. PubMed ID: 11303067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of human ether-à-go-go-related K+ (HERG) channel inactivation by Cs+ and K+.
    Zhang S; Kehl SJ; Fedida D
    J Physiol; 2003 May; 548(Pt 3):691-702. PubMed ID: 12626667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
    Perrin MJ; Kuchel PW; Campbell TJ; Vandenberg JI
    Mol Pharmacol; 2008 Nov; 74(5):1443-52. PubMed ID: 18701618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.